# A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer

> **NCT01495676** · NA · TERMINATED · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle** · enrollment: 69 (actual)

## Conditions studied

- Infiltrating Bladder Urothelial Carcinoma

## Interventions

- **OTHER:** Radiation + cisplatin
- **OTHER:** Radiation + cisplatin + gemcitabine

## Key facts

- **NCT ID:** NCT01495676
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07-06
- **Primary completion:** 2022-07-25
- **Final completion:** 2024-12-07
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01495676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01495676, "A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01495676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*